At a median follow-up of 1.5 years, promising data from the 320 mg expansion cohort of phase 1/1b study shows no progression in patients with treatment-naïve CLL treated with sonrotoclax, a ...
Denver Post Newsroom: 303-954-1201 or [email protected] Customer Service: Customer service is open Monday-Friday from 6:30 a.m.-5 p.m., Saturday from 7 a.m.-10 a.m. and Sunday from 8:30 a ...